EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today a financial and business update for the first quarter ended March 31, 2011. Revenue was constant for the first quarter of 2011 and 2010 at $0.2 million. Net loss for the first quarter of 2011 was $17.1 million, compared to net loss of $4.7 million for the first quarter of 2010. The increase in the net loss for the first quarter 2011 is due primarily to the revaluation of the warrant liability and derivative liability associated with the outstanding warrants and preferred stock, respectively, that the Company has issued in its financing transactions.
